[ad_1]
The US pharmaceutical company Moderna was the first company to apply for approval of a corona vaccine in the EU on Monday. The big vaccination could start in December. The name of the Modern vaccine: mRNA-1273.
The main facts about the vaccine
► The effectiveness according to the manufacturer: 94.1 percent. This comes from the latest analysis of data from the phase III clinical trial, which involved 30,000 people in the United States.
► Half of the participants received the vaccine, the other half a placebo. Two doses 28 days apart are needed for complete protection from vaccination.
► The US company vaccine can be stored at normal refrigerator temperature. The agent is supposed to be stable for 30 days at temperatures of 2-8 degrees, according to an announcement by Moderna in mid-November.
► There were 196 cases of Covid-19 among the 30,000 subjects. Of these, 185 received an ineffective placebo and eleven received the vaccine.
► Moderna reports 30 serious cases, all of which occurred in the placebo group. The company concludes that the vaccine is 100 percent effective in protecting against serious diseases.
► The most common side effects of the vaccine include tiredness, redness and pain at the injection site, as well as headaches and body aches. Some participants showed flu-like symptoms.
► The protection provided by the vaccine is the same regardless of age, sex and ethnic origin, Moderna explained. Before the end of the year, the company wants to start a new study to test the vaccine in adolescents so that they can have a vaccine available by September of next year.
► The prospect of a vaccine that will soon be ready for use sent the German Dax stock index to 13,422 points on Monday afternoon, the highest level since early September.
How does an mRNA vaccine work?
It contains genetic information about the pathogen, from which the body produces a viral protein. The goal of vaccination is to stimulate the immune system to produce antibodies to intercept viruses. There is no approved vaccine of this type yet, and therefore there is no long-term experience.
Last week, the head of the EU Commission, Ursula von der Leyen, announced that a framework contract for up to 160 million doses of vaccines had been concluded with Moderna, a company founded in 2010. According to Moderna, delivery could begin in December.
The European Medicines Agency Ema has been running a continuous review process for a long time, the aim of which is to speed up the approval process: manufacturers submit individual parts on quality, safety and efficacy before the full application for approval.
